<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="case-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Intern Med</journal-id>
      <journal-id journal-id-type="iso-abbrev">Intern. Med</journal-id>
      <journal-id journal-id-type="doi">10.2169/internalmedicine.55.6869</journal-id>
      <journal-title-group>
        <journal-title>Internal Medicine</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0918-2918</issn>
      <issn pub-type="epub">1349-7235</issn>
      <publisher>
        <publisher-name>The Japanese Society of Internal Medicine</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">27853067</article-id>
      <article-id pub-id-type="pmc">5173492</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Surgical Resection for Hepatocellular Carcinoma with Cardiac Cirrhosis after the Fontan Procedure</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Takuma</surname>
            <given-names>Yoshitaka</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Fukada</surname>
            <given-names>Yuji</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Iwadou</surname>
            <given-names>Shota</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Miyatake</surname>
            <given-names>Hirokazu</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Uematsu</surname>
            <given-names>Shuji</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Okamoto</surname>
            <given-names>Ryoichi</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Sato</surname>
            <given-names>Daisuke</given-names>
          </name>
          <xref ref-type="aff" rid="aff2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Matsukawa</surname>
            <given-names>Hiroyoshi</given-names>
          </name>
          <xref ref-type="aff" rid="aff2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Shiozaki</surname>
            <given-names>Shigehiro</given-names>
          </name>
          <xref ref-type="aff" rid="aff2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Kamada</surname>
            <given-names>Masahiro</given-names>
          </name>
          <xref ref-type="aff" rid="aff3">3</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Morito</surname>
            <given-names>Toshiaki</given-names>
          </name>
          <xref ref-type="aff" rid="aff4">4</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Araki</surname>
            <given-names>Yasuyuki</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
        </contrib>
        <aff id="aff1"><label>1</label>Department of Internal Medicine, Hiroshima City Hospital, Japan</aff>
        <aff id="aff2"><label>2</label>Department of Surgery, Hiroshima City Hospital, Japan</aff>
        <aff id="aff3"><label>3</label>Department of Pediatric Cardiology, Hiroshima City Hospital, Japan</aff>
        <aff id="aff4"><label>4</label>Department of Pathology, Hiroshima City Hospital, Japan</aff>
      </contrib-group>
      <author-notes>
        <fn>
          <p>Correspondence to Dr.&#x3000;Yoshitaka Takuma, <email>takuma@enjoy.ne.jp</email></p>
        </fn>
      </author-notes>
      <pub-date pub-type="ppub">
        <day>15</day>
        <month>11</month>
        <year>2016</year>
      </pub-date>
      <volume>55</volume>
      <issue>22</issue>
      <fpage>3265</fpage>
      <lpage>3272</lpage>
      <history>
        <date date-type="received">
          <day>20</day>
          <month>11</month>
          <year>2015</year>
        </date>
        <date date-type="accepted">
          <day>7</day>
          <month>1</month>
          <year>2016</year>
        </date>
      </history>
      <permissions>
        <license license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
          <license-p><!--CREATIVE COMMONS-->The Internal Medicine is an Open Access article distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view the details of this license, please visit (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">https://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link>).</license-p>
        </license>
      </permissions>
      <abstract>
        <p>A 29-year-old woman who underwent the Fontan procedure at 10 years of age had an incidental finding of liver masses on abdominal ultrasonography. Subsequent gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid magnetic resonance imaging showed a 15 mm hypervascular mass with washout in the hepatobiliary phase in liver segment 4 (S4), and an 18 mm hypervascular mass without washout in the hepatobiliary phase in liver segment 2 (S2). The S2 liver mass was pathologically diagnosed to be a regenerative nodule by an ultrasound-guided needle biopsy, and the S4 liver mass was pathologically diagnosed as a poorly differentiated hepatocellular carcinoma after partial hepatectomy. </p>
      </abstract>
      <kwd-group kwd-group-type="author">
        <kwd>hepatocellular carcinoma (HCC)</kwd>
        <kwd>Fontan</kwd>
        <kwd>cardiac cirrhosis</kwd>
        <kwd>surgical resection</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec>
      <title>Introduction</title>
      <p>The Fontan procedure is used to separate the systemic and pulmonary circulations in patients with various forms of functionally univentricular hearts. In the Fontan circulation, systemic venous return is sent to the pulmonary arteries without passage through a ventricle. The Fontan procedure can result in various late complications, including central venous hypertension, diminished oxygen delivery, reduced cardiac output, venous thrombosis, and arrhythmia (<xref rid="B1" ref-type="bibr">1</xref>,<xref rid="B2" ref-type="bibr">2</xref>). These complications caused by central venous hypertension lead to parenchymal injury, fibrosis, and cirrhosis of the liver (<xref rid="B2" ref-type="bibr">2</xref>,<xref rid="B3" ref-type="bibr">3</xref>). Cardiac cirrhosis is a serious late complication of congenital heart disease and can cause hepatocellular carcinoma (HCC) (<xref rid="B4" ref-type="bibr">4</xref>,<xref rid="B5" ref-type="bibr">5</xref>). However, the prevalence and risk factors of cirrhotic changes and HCCs have not been clearly identified. Furthermore, non-invasive diagnostic tools for hepatic fibrosis and the management of HCC in patients after undergoing the Fontan procedure have not yet been clearly established.</p>
      <p>We herein report a case of HCC with cardiac cirrhosis treated with surgical resection.</p>
    </sec>
    <sec>
      <title>Case Report</title>
      <p>A 29-year-old woman with a history of a univentricular heart had undergone a Fontan operation 10 years of age. She also had situs inversus. She was followed-up at the department of pediatric cardiology in our hospital, and regularly underwent blood examinations without alpha-fetoprotein (AFP) at 2- or 3-month intervals. The results showed that the transaminase level was within the normal range. On a routine follow-up day, she experienced slight abdominal discomfort and received abdominal ultrasonography (US). She had an incidental finding of liver masses and was referred to our department.</p>
      <p>B-mode conventional US showed a 15 mm hypoechoic mass in liver segment 4 (S4) (<xref ref-type="fig" rid="g001">Fig. 1a</xref>), and an 18 mm hyperechoic mass in liver segment 2 (S2) (<xref ref-type="fig" rid="g002">Fig. 2a</xref>). Furthermore, the liver parenchyma had a coarsened appearance consistent with cirrhosis, and ascites and splenomegaly were observed (<xref ref-type="fig" rid="g001">Fig. 1b and c</xref>).</p>
      <fig id="g001" orientation="portrait" position="float">
        <label>Figure 1.</label>
        <caption>
          <p>Ultrasonography &#xFB01;ndings (arrows). B-mode conventional ultrasonography showed a 15 mm hypoechoic mass in liver segment 4 (S4) (a), the liver parenchyma had a coarsened appearance consistent with cirrhosis, and ascites and splenomegaly were observed (b, c).CEUS using Sonazoid showed a homogeneously enhanced mass in the arterial dominant phase (d), a hypoechoic mass relative to the adjacent liver parenchyma during the portal dominant phase (e), and a contrast defect with a clear border in the postvascular phase (f).</p>
        </caption>
        <graphic xlink:href="1349-7235-55-3265-g001"/>
      </fig>
      <fig id="g002" orientation="portrait" position="float">
        <label>Figure 2.</label>
        <caption>
          <p>B-mode conventional ultrasonography showed an 18 mm hyperechoic mass in liver segment 2 (S2) (a); and CEUS showed a homogeneously enhanced mass in the arterial dominant phase (b), isoechoic mass relative to the adjacent liver parenchyma during the portal dominant phase (c), and no defects in the postvascular phase (d).</p>
        </caption>
        <graphic xlink:href="1349-7235-55-3265-g002"/>
      </fig>
      <p>We next performed contrast-enhanced US (CEUS) using a bolus injection of 0.015 mL/kg Sonazoid (perfluorobutane; Daiichi-Sankyo, Tokyo, Japan). The mass lesion in S4 was homogeneously enhanced in the arterial dominant phase (from 10 to 30 seconds) (<xref ref-type="fig" rid="g001">Fig. 1d</xref>). The lesion became progressively hypoechoic relative to the adjacent liver parenchyma during the portal dominant phase (from 30 to 120 seconds) (<xref ref-type="fig" rid="g001">Fig. 1e</xref>), and provided a contrast defect with a clear border in the postvascular phase (10 minutes later) (<xref ref-type="fig" rid="g001">Fig. 1f</xref>). The mass lesion in S2 was homogeneously enhanced in the arterial dominant phase (<xref ref-type="fig" rid="g002">Fig. 2b</xref>). The lesion became isoechoic mass relative to the adjacent liver parenchyma during the portal dominant phase (<xref ref-type="fig" rid="g002">Fig. 2c</xref>) and provided no defects in the postvascular phase (10 minutes later) (<xref ref-type="fig" rid="g002">Fig. 2d</xref>).</p>
      <p>We subsequently performed magnetic resonance imaging (MRI) with conventional T1-and T2-weighted imaging (WI) before and after contrast media administration, including diffusion imaging. The contrast media used was hepatocyte-specific Primovist [gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid (Gd-EOB-DTPA); Bayer Schering Pharma, Berlin, Germany]. There was radiographic evidence of liver cirrhosis with portal hypertension, including a nodular surface, a coarse texture, ascites, and splenomegaly on MRI (<xref ref-type="fig" rid="g003">Fig. 3a and b</xref>).</p>
      <fig id="g003" orientation="portrait" position="float">
        <label>Figure 3.</label>
        <caption>
          <p>There was radiographic evidence of liver cirrhosis with portal hypertension, including a nodular surface, a coarse texture, ascites, and splenomegaly on MRI (a, b). Gd-EOB-DTPA MRI showed a 15 mm S4 mass with a moderately low intensity in T1-WI (c), moderately high intensity in T2-WI (d), moderately high intensity in diffusion (e), homogeneous arterial enhancement (b, f), and complete washout in the hepatobiliary phase (g).</p>
        </caption>
        <graphic xlink:href="1349-7235-55-3265-g003"/>
      </fig>
      <p>This imaging revealed a mass lesion in S4 with a moderately low intensity in T1-WI (<xref ref-type="fig" rid="g003">Fig. 3c</xref>) and moderately high intensity in T2-WI (<xref ref-type="fig" rid="g003">Fig. 3d</xref>). In diffusion imaging, the lesion showed a moderately high intensity (<xref ref-type="fig" rid="g003">Fig. 3e</xref>). In the postcontrast phases, the lesion revealed homogeneous enhancement in the arterial phase at 20 seconds (<xref ref-type="fig" rid="g003">Fig. 3b and f</xref>), and washout in the portal phase at 70 seconds and interstitial phase at 180 seconds. At 20 minutes (hepatobiliary phase) after the contrast uptake the lesion showed washout (<xref ref-type="fig" rid="g003">Fig. 3g</xref>). According to these findings, a final diagnosis of HCC was made. In addition, MRI imaging revealed a mass lesion in S2 with a moderately high intensity in T1-WI (<xref ref-type="fig" rid="g004">Fig. 4b</xref>) and moderately low intensity in T2-WI (<xref ref-type="fig" rid="g004">Fig. 4c</xref>). In diffusion imaging, the lesion showed a moderately low intensity (<xref ref-type="fig" rid="g004">Fig. 4d</xref>). In the postcontrast phases, the lesion revealed a homogeneous enhancement in the arterial phase (<xref ref-type="fig" rid="g004">Fig. 4a and e</xref>), an isoenhancement relative to the adjacent liver parenchyma in the portal and interstitial phases, and a high intensity in the hepatobiliary phase (<xref ref-type="fig" rid="g004">Fig. 4f</xref>).</p>
      <fig id="g004" orientation="portrait" position="float">
        <label>Figure 4.</label>
        <caption>
          <p>Gd-EOB-DTPA MRI showed an 18 mm S2 mass with a moderately high intensity in T1-WI (b), moderately low intensity in T2-WI (c), moderately low intensity in diffusion (d), homogeneous arterial enhancement (a, e), and high intensity in the hepatobiliary phase (f).</p>
        </caption>
        <graphic xlink:href="1349-7235-55-3265-g004"/>
      </fig>
      <p>The laboratory data are given in <xref ref-type="table" rid="t001">Table 1</xref>. Her liver function was well preserved with the Child-Pugh classification A, and her international normalized ratio was low (the patient was on warfarin for atrial arrhythmia). Other lab findings included a high AFP level [normal less than 40 nanograms/milliliter (ng/mL)], high Lens culinaris agglutinin-reactive fraction of AFP (AFP-L3) (normal less than 10%), low platelet count (normal greater than 150,000/microliter), high hyaluronic acid (normal less than 50 ng/mL), and high type IV collagen 7S (normal less than 6.0 ng/mL). An echocardiogram demonstrated a normal ventricular function and no obstruction in the Fontan circuit. The patient had no other significant medical problems and no other risk factors for cirrhosis, as she expressed negativity for viral and autoimmune markers, no alcoholic consumption, no hepatotoxic drugs (such as amiodarone), and no metabolic factors such as diabetes mellitus, obesity (her body mass index was 17.7), or fatty liver in US. Following the reversal of her warfarin therapy, an ultrasound-guided needle biopsy of the S2 lesion was performed. Histological findings revealed that bridging fibrosis in the liver section, and the parenchymal cells did not display cellular or structural atypia (<xref ref-type="fig" rid="g005">Fig. 5</xref>). The liver mass in S2 was pathologically diagnosed to be a regenerative nodule.</p>
      <table-wrap id="t001" orientation="portrait" position="float">
        <label>Table 1.</label>
        <caption>
          <p>Results of Blood Tests.</p>
        </caption>
        <table frame="hsides" rules="groups">
          <tbody>
            <tr>
              <td rowspan="1" colspan="1">
                <bold>Hematology</bold>
              </td>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1">
                <bold>Blood biochemistry</bold>
              </td>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1">
                <bold>Serology</bold>
              </td>
              <td rowspan="1" colspan="1"/>
            </tr>
            <tr>
              <td style="padding-left:1em;" rowspan="1" colspan="1"> WBC </td>
              <td align="center" rowspan="1" colspan="1">3.0 &#xD7;10<sup>3</sup> /&#x3BC;L</td>
              <td style="padding-left:2em;" rowspan="1" colspan="1"> TP </td>
              <td align="right" rowspan="1" colspan="1">7.7 g/dL </td>
              <td rowspan="1" colspan="1"> HBsAg </td>
              <td align="center" rowspan="1" colspan="1">(-)</td>
            </tr>
            <tr>
              <td style="padding-left:1em;" rowspan="1" colspan="1"> RBC </td>
              <td align="center" rowspan="1" colspan="1">494&#xD7;10<sup>4</sup> /&#x3BC;L</td>
              <td style="padding-left:2em;" rowspan="1" colspan="1"> Alb </td>
              <td align="right" rowspan="1" colspan="1">4.9 g/dL </td>
              <td rowspan="1" colspan="1"> HBsAb </td>
              <td align="center" rowspan="1" colspan="1">(-)</td>
            </tr>
            <tr>
              <td style="padding-left:1em;" rowspan="1" colspan="1"> Hb </td>
              <td align="center" rowspan="1" colspan="1">9.5 g/dL</td>
              <td style="padding-left:2em;" rowspan="1" colspan="1"> ChE </td>
              <td align="right" rowspan="1" colspan="1">166 IU/L </td>
              <td rowspan="1" colspan="1"> HBcAb </td>
              <td align="center" rowspan="1" colspan="1">(-)</td>
            </tr>
            <tr>
              <td style="padding-left:1em;" rowspan="1" colspan="1"> Hct </td>
              <td align="center" rowspan="1" colspan="1">32.7 %</td>
              <td style="padding-left:2em;" rowspan="1" colspan="1"> T.Bil </td>
              <td align="right" rowspan="1" colspan="1">1.0 mg/dL </td>
              <td rowspan="1" colspan="1"> HCV-Ab </td>
              <td align="center" rowspan="1" colspan="1">(-)</td>
            </tr>
            <tr>
              <td style="padding-left:1em;" rowspan="1" colspan="1"> PLT </td>
              <td align="center" rowspan="1" colspan="1">12.5&#xD7;10<sup>4</sup> /&#x3BC;L</td>
              <td style="padding-left:2em;" rowspan="1" colspan="1"> D.Bil </td>
              <td align="right" rowspan="1" colspan="1">0.5 mg/dL </td>
              <td rowspan="1" colspan="1"> ANA </td>
              <td align="center" rowspan="1" colspan="1">(-)</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td style="padding-left:2em;" rowspan="1" colspan="1"> AST </td>
              <td align="right" rowspan="1" colspan="1">23 IU/L </td>
              <td rowspan="1" colspan="1"> AMA-M2 </td>
              <td align="center" rowspan="1" colspan="1">(-)</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td style="padding-left:2em;" rowspan="1" colspan="1"> ALT </td>
              <td align="right" rowspan="1" colspan="1">13 IU/L </td>
              <td rowspan="1" colspan="1"> IgG </td>
              <td align="center" rowspan="1" colspan="1">1,267 mg/dL</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">
                <bold>Coagulation test</bold>
              </td>
              <td rowspan="1" colspan="1"/>
              <td style="padding-left:2em;" rowspan="1" colspan="1"> LDH </td>
              <td align="right" rowspan="1" colspan="1">226 IU/L </td>
              <td rowspan="1" colspan="1"> IgA </td>
              <td align="center" rowspan="1" colspan="1">233 mg/dL</td>
            </tr>
            <tr>
              <td style="padding-left:1em;" rowspan="1" colspan="1"> PT% </td>
              <td align="center" rowspan="1" colspan="1">33.1 %</td>
              <td style="padding-left:2em;" rowspan="1" colspan="1"> ALP </td>
              <td align="right" rowspan="1" colspan="1">163 IU/L </td>
              <td rowspan="1" colspan="1"> IgM </td>
              <td align="center" rowspan="1" colspan="1">231 mg/dL</td>
            </tr>
            <tr>
              <td style="padding-left:1em;" rowspan="1" colspan="1"> PT-INR </td>
              <td align="center" rowspan="1" colspan="1">1.68</td>
              <td style="padding-left:2em;" rowspan="1" colspan="1"> &#x3B3;-GTP </td>
              <td align="right" rowspan="1" colspan="1">47 IU/L </td>
              <td rowspan="1" colspan="1"> AFP </td>
              <td align="center" rowspan="1" colspan="1">117.1 ng/mL</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td style="padding-left:2em;" rowspan="1" colspan="1"> ZTT </td>
              <td align="right" rowspan="1" colspan="1">8.5 KU </td>
              <td rowspan="1" colspan="1"> AFP-L3 </td>
              <td align="center" rowspan="1" colspan="1">46.8 %</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td style="padding-left:2em;" rowspan="1" colspan="1"> TTT </td>
              <td align="right" rowspan="1" colspan="1">4.6 KU </td>
              <td rowspan="1" colspan="1"> CEA </td>
              <td align="center" rowspan="1" colspan="1">0.4 ng/mL</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td style="padding-left:2em;" rowspan="1" colspan="1"> BUN </td>
              <td align="right" rowspan="1" colspan="1">19 mg/dL </td>
              <td rowspan="1" colspan="1"> CA19-9 </td>
              <td align="center" rowspan="1" colspan="1">5.1 ng/mL</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td style="padding-left:2em;" rowspan="1" colspan="1"> Cr </td>
              <td align="right" rowspan="1" colspan="1">0.79 mg/dL</td>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td style="padding-left:2em;" rowspan="1" colspan="1"> CRP </td>
              <td align="right" rowspan="1" colspan="1">0.010 mg/dL</td>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td style="padding-left:2em;" rowspan="1" colspan="1"> hyaluronic acid </td>
              <td align="right" rowspan="1" colspan="1">53 ng/mL</td>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td style="padding-left:2em;" rowspan="1" colspan="1"> type IV collagen7S </td>
              <td align="right" rowspan="1" colspan="1">8.5 ng/mL</td>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td style="padding-left:2em;" rowspan="1" colspan="1"> ICG-R15 </td>
              <td align="right" rowspan="1" colspan="1">19.9 %</td>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
            </tr>
          </tbody>
        </table>
        <table-wrap-foot>
          <fn>
            <p>WBC: white blood cells, RBC: red blood cells, Hb: hemoglobin, Hct: hematocrit, PLT: platelets, PT: prothrombin time, INR: international normalized ratio, TP: total protein, Alb: albumin, ChE: cholinesterase, T.Bil: total bilirubin, D.Bil: direct bilirubin, AST: aspartate aminotransferase, ALT: alanine aminotransferase, LDH: lactate dehydrogenase, ALP: alkaline phosphatase, &#x3B3;-GTP: &#x3B3;-glutamyltranspeptidase, ZTT: zinc sulfate turbidity test, TTT: thymol turbidity test, BUN: blood urea nitrogen, Cr: creatinine, CRP: C-reactive protein, ICG-R: indocyanine green retention, HBsAg: hepatitis B surface antigen, HBsAb: hepatitis B surface antibody, HBcAb: hepatitis B core antibody, HCV: hepatitis C virus antibody, ANA: antinuclear antibodies, AMA-M2: anti-mitochondrial M2 antibody, AFP: alpha-fetoprotein, AFP-L3: Lens culinaris agglutinin-reactive fraction of AFP, CEA: carcinoembryonic antigen, CA: carbohydrate antigen</p>
          </fn>
        </table-wrap-foot>
      </table-wrap>
      <fig id="g005" orientation="portrait" position="float">
        <label>Figure 5.</label>
        <caption>
          <p>A histological specimen was obtained by an ultrasound-guided needle biopsy of the S2 lesion. Microscopic histological findings revealed bridging fibrosis in the liver section. The parenchymal cells did not display cellular or structural atypia [Hematoxylin and Eosin staining (a), and silver impregnation (b) with a low-power field]. The liver mass in S2 was pathologically diagnosed as a regenerative nodule.</p>
        </caption>
        <graphic xlink:href="1349-7235-55-3265-g005"/>
      </fig>
      <p>The patient underwent a curative operation, involving partial hepatectomy of S4 in the liver. Macroscopically, sections of the specimen revealed a yellowish-white encapsulated solid tumor measuring 15 mm in size (<xref ref-type="fig" rid="g006">Fig. 6a</xref>).</p>
      <fig id="g006" orientation="portrait" position="float">
        <label>Figure 6.</label>
        <caption>
          <p>A macroscopic appearance of the resected S4 specimen revealed a yellowish-white encapsulated solid tumor measuring 15 mm in size (a). Microscopically, the growth pattern of the S4 liver tumor showed expansive growth with extracapsular invasions [b, Hematoxylin and Eosin (H&amp;E) staining with a low-power field]. Tumor cells had an increased nuclear/cytoplasmic ratio, polymorphic, and chromatin-rich nuclei, and the pathological diagnosis was poorly differentiated HCC (c, H&amp;E staining with a high-power field).</p>
        </caption>
        <graphic xlink:href="1349-7235-55-3265-g006"/>
      </fig>
      <p>The growth pattern of the liver tumor showed expansive growth with extracapsular invasions (<xref ref-type="fig" rid="g006">Fig. 6b</xref>). The tumor cells had an increased nuclear/cytoplasmic ratio, polymorphic, and chromatin-rich nuclei, and the pathological diagnosis was poorly differentiated HCC (<xref ref-type="fig" rid="g006">Fig. 6c</xref>). The non-cancerous area of the resected specimen revealed that bridging fibrosis was observed without fat deposition, and the patient was diagnosed with liver cirrhosis (<xref ref-type="fig" rid="g007">Fig. 7a</xref>). Fibrosis was observed in both the portal and pericellular areas, the sinusoidal structure was maintained, but no signi&#xFB01;cant inflammation was observed (<xref ref-type="fig" rid="g007">Fig. 7b and c</xref>).</p>
      <fig id="g007" orientation="portrait" position="float">
        <label>Figure 7.</label>
        <caption>
          <p>The noncancerous area of the resected specimen revealed bridging fibrosis without fat deposition, and the patient was diagnosed with liver cirrhosis [silver impregnation (a)]. Fibrosis was observed in both the portal and pericellular areas, the sinusoidal structure was maintained, and signi&#xFB01;cant in&#xFB02;ammation was not seen [silver impregnation (b, c) with a high-power field].</p>
        </caption>
        <graphic xlink:href="1349-7235-55-3265-g007"/>
      </fig>
      <p>After discharge from the hospital, the patient was followed-up at 3-month intervals.</p>
      <p>At the 1-year follow-up, her AFP level was 2.7 ng/mL, AFP-L3 was less than 0.5%, and the tumor markers remained normal. Furthermore, US and MRI showed no evidence of HCC recurrence.</p>
    </sec>
    <sec>
      <title>Discussion</title>
      <p>In the present case, there were no known etiological factors such as hepatitis viral infection, alcoholic liver disease, autoimmune liver diseases, autoimmune hepatitis, primary biliary cirrhosis, metabolic liver diseases [such as non-alcoholic steatohepatitis (NASH)], or medication with hepatotoxic drugs (such as amiodarone). Moreover, significant hepatic inflammation or fat deposition was not seen as a result of processes such as hepatitis viral infection or NASH. On histology in the present case, hepatic sinusoidal fibrosis extending from centrilobular areas toward the portal tract without inflammation were observed. Schwarz et al. discussed that hepatic fibrosis after the Fontan procedure was a mixed disease that affects both the portal and centrilobular areas in liver biopsy and autopsy specimens (<xref rid="B6" ref-type="bibr">6</xref>,<xref rid="B7" ref-type="bibr">7</xref>). Sinusoidal fibrosis is believed to result from an increase in central venous pressure transmitted to hepatic cells that surround the central veins, because the extent of cirrhosis is strongly correlated with elevated hepatic venous pressures and a low cardiac index in patients after undergoing the Fontan procedure (<xref rid="B8" ref-type="bibr">8</xref>). After Fontan palliation, a significant liver disease can result in central venous congestion and hypoxia resulting from a low cardiac output, however, little is known regarding fibrogenic mechanisms independent of the inflammation-mediated pathway in congestive liver disease (CLD). In CLD, mechanotransduction associated with stretching and compression of hepatic stellate cells may be a potent inducer of hepatic fibrosis (<xref rid="B9" ref-type="bibr">9</xref>,<xref rid="B10" ref-type="bibr">10</xref>). Using a newly characterized murine CLD model, sinusoidal thrombosis and mechanical stretching of adjacent hepatic stellate cells caused by sinusoidal dilatation was shown to induce the release of fibronectin by hepatic stellate cells, and both fibrin and stretching stimulated fibronectin fibril assembly through a &#x3B2;1-integrin and actin-dependent mechanism (<xref rid="B11" ref-type="bibr">11</xref>).</p>
      <p>In addition, hepatic complications after the Fontan procedure are associated with the duration of follow-up (<xref rid="B8" ref-type="bibr">8</xref>,<xref rid="B12" ref-type="bibr">12</xref>). Progression to cirrhosis may even be observed within 10 years after the initial Fontan procedure (<xref rid="B13" ref-type="bibr">13</xref>). In 34 patients with a median follow-up of 11.5 years after the Fontan procedure, 30% experienced abnormal transaminases, 61% abnormal &#x3B3;-GTP, 32% abnormal bilirubin, and 58% coagulopathy (<xref rid="B14" ref-type="bibr">14</xref>). As compared to a duration of 0-5 years, the odds ratio of hepatic complications was 4.4 for a post-Fontan duration of 11-15 years and 9.0 for a duration of 16-20 years, respectively (<xref rid="B12" ref-type="bibr">12</xref>).</p>
      <p>Liver cirrhosis is a potential prerequisite for HCC, however, the prevalence and progression of cirrhotic changes in the Fontan population have not been clearly identified. Non-invasive diagnostic tools for hepatic fibrosis are needed, because a liver biopsy, the golden standard for diagnosing liver cirrhosis, is difficult to perform in Fontan patients due to prophylactic anticoagulation. Similar to the present case, a radiological assessment of liver fibrosis using various methods such as US, CT, or MRI may be useful.</p>
      <p>There are several reports of HCC in patients with CLD following the Fontan procedure.</p>
      <p>As shown in <xref ref-type="table" rid="t002">Table 2</xref>, a recent PubMed search identified 12 cases of HCCs among published reports. The publications described the use of surgical resection, transcatheter arterial chemoembolization, radioembolization, local ablation, or sorafenib therapy (<xref rid="B15" ref-type="bibr">15</xref>-<xref rid="B22" ref-type="bibr">22</xref>). In previous reports, two patients were treated with surgical resection (<xref rid="B20" ref-type="bibr">20</xref>,<xref rid="B21" ref-type="bibr">21</xref>). For early stage HCC, surgical resection provides curative treatment with a long-time survival, however, hepatectomy is rarely performed following the Fontan procedure because it is difficult to detect early stage HCCs. Although the present patient did not receive periodic surveillance for HCC, such as US and AFP, it is fortunate that early stage HCC was incidentally detected. HCC detected after the onset of symptoms has a poor prognosis (5-year survival rate of 0-10%). In contrast, early stage HCCs detected by surveillance can be cured with both surgical resection and liver transplantation (5-year disease-free survival rate &gt;50%) (<xref rid="B23" ref-type="bibr">23</xref>).</p>
      <table-wrap id="t002" orientation="portrait" position="float">
        <label>Table 2.</label>
        <caption>
          <p>Reported Cases of Hepatocellular Carcinoma after Fontan Procedure.</p>
        </caption>
        <table frame="hsides" rules="groups">
          <thead style="border-top:solid thin; border-bottom:solid thin;">
            <tr>
              <th align="left" rowspan="1" colspan="1">Reference</th>
              <th rowspan="1" colspan="1">No. of cases</th>
              <th rowspan="1" colspan="1">Age(y)</th>
              <th rowspan="1" colspan="1">Sex</th>
              <th rowspan="1" colspan="1">AFP (ng/mL)</th>
              <th rowspan="1" colspan="1">Size (mm)</th>
              <th align="left" rowspan="1" colspan="1">Treatment</th>
              <th rowspan="1" colspan="1">Outcome</th>
            </tr>
          </thead>
          <tbody style="border-top:solid thin; border-bottom:solid thin;">
            <tr>
              <td style="padding-left:1em;" rowspan="1" colspan="1"> 15</td>
              <td align="center" rowspan="1" colspan="1">1</td>
              <td align="center" rowspan="1" colspan="1">24</td>
              <td align="center" rowspan="1" colspan="1">M</td>
              <td align="center" rowspan="1" colspan="1">ND</td>
              <td align="center" rowspan="1" colspan="1">40</td>
              <td align="left" rowspan="1" colspan="1">ND</td>
              <td align="center" rowspan="1" colspan="1">Died</td>
            </tr>
            <tr>
              <td style="padding-left:1em;" rowspan="1" colspan="1"> 16</td>
              <td align="center" rowspan="1" colspan="1">2</td>
              <td align="center" rowspan="1" colspan="1">27</td>
              <td align="center" rowspan="1" colspan="1">F</td>
              <td align="center" rowspan="1" colspan="1">162.7</td>
              <td align="center" rowspan="1" colspan="1">22.1</td>
              <td rowspan="1" colspan="1">Systemic chemo</td>
              <td align="center" rowspan="1" colspan="1">Died</td>
            </tr>
            <tr>
              <td style="padding-left:1em;" rowspan="1" colspan="1"/>
              <td align="center" rowspan="1" colspan="1"/>
              <td align="center" rowspan="1" colspan="1">28</td>
              <td align="center" rowspan="1" colspan="1">F</td>
              <td align="center" rowspan="1" colspan="1">788</td>
              <td align="center" rowspan="1" colspan="1">40</td>
              <td rowspan="1" colspan="1">Sorafenib</td>
              <td align="center" rowspan="1" colspan="1">Died</td>
            </tr>
            <tr>
              <td style="padding-left:1em;" rowspan="1" colspan="1"> 17</td>
              <td align="center" rowspan="1" colspan="1">4</td>
              <td align="center" rowspan="1" colspan="1">32</td>
              <td align="center" rowspan="1" colspan="1">F</td>
              <td align="center" rowspan="1" colspan="1">700</td>
              <td align="center" rowspan="1" colspan="1">40</td>
              <td rowspan="1" colspan="1">TACE</td>
              <td align="center" rowspan="1" colspan="1">Alive</td>
            </tr>
            <tr>
              <td style="padding-left:1em;" rowspan="1" colspan="1"/>
              <td align="center" rowspan="1" colspan="1"/>
              <td align="center" rowspan="1" colspan="1">24</td>
              <td align="center" rowspan="1" colspan="1">M</td>
              <td align="center" rowspan="1" colspan="1">5,000</td>
              <td align="center" rowspan="1" colspan="1">ND</td>
              <td rowspan="1" colspan="1">ND</td>
              <td align="center" rowspan="1" colspan="1">Died</td>
            </tr>
            <tr>
              <td style="padding-left:1em;" rowspan="1" colspan="1"/>
              <td align="center" rowspan="1" colspan="1"/>
              <td align="center" rowspan="1" colspan="1">33</td>
              <td align="center" rowspan="1" colspan="1">M</td>
              <td align="center" rowspan="1" colspan="1">630</td>
              <td align="center" rowspan="1" colspan="1">ND</td>
              <td rowspan="1" colspan="1">Radioembolization</td>
              <td align="center" rowspan="1" colspan="1">Died</td>
            </tr>
            <tr>
              <td style="padding-left:1em;" rowspan="1" colspan="1"/>
              <td align="center" rowspan="1" colspan="1"/>
              <td align="center" rowspan="1" colspan="1">42</td>
              <td align="center" rowspan="1" colspan="1">F</td>
              <td align="center" rowspan="1" colspan="1">106</td>
              <td align="center" rowspan="1" colspan="1">ND</td>
              <td rowspan="1" colspan="1">TACE</td>
              <td align="center" rowspan="1" colspan="1">Alive</td>
            </tr>
            <tr>
              <td style="padding-left:1em;" rowspan="1" colspan="1"> 18</td>
              <td align="center" rowspan="1" colspan="1">1</td>
              <td align="center" rowspan="1" colspan="1">51</td>
              <td align="center" rowspan="1" colspan="1">M</td>
              <td align="center" rowspan="1" colspan="1">ND</td>
              <td align="center" rowspan="1" colspan="1">10</td>
              <td rowspan="1" colspan="1">Local ablation</td>
              <td align="center" rowspan="1" colspan="1">Alive</td>
            </tr>
            <tr>
              <td style="padding-left:1em;" rowspan="1" colspan="1"> 19</td>
              <td align="center" rowspan="1" colspan="1">1</td>
              <td align="center" rowspan="1" colspan="1">19</td>
              <td align="center" rowspan="1" colspan="1">F</td>
              <td align="center" rowspan="1" colspan="1">ND</td>
              <td align="center" rowspan="1" colspan="1">ND</td>
              <td rowspan="1" colspan="1">Sorafenib</td>
              <td align="center" rowspan="1" colspan="1">Died</td>
            </tr>
            <tr>
              <td style="padding-left:1em;" rowspan="1" colspan="1"> 20</td>
              <td align="center" rowspan="1" colspan="1">1</td>
              <td align="center" rowspan="1" colspan="1">23</td>
              <td align="center" rowspan="1" colspan="1">F</td>
              <td align="center" rowspan="1" colspan="1">ND</td>
              <td align="center" rowspan="1" colspan="1">148</td>
              <td rowspan="1" colspan="1">Surgical resection</td>
              <td align="center" rowspan="1" colspan="1">Alive</td>
            </tr>
            <tr>
              <td style="padding-left:1em;" rowspan="1" colspan="1"> 21</td>
              <td align="center" rowspan="1" colspan="1">1</td>
              <td align="center" rowspan="1" colspan="1">32</td>
              <td align="center" rowspan="1" colspan="1">M</td>
              <td align="center" rowspan="1" colspan="1">13</td>
              <td align="center" rowspan="1" colspan="1">40</td>
              <td rowspan="1" colspan="1">Surgical resection</td>
              <td align="center" rowspan="1" colspan="1">Alive</td>
            </tr>
            <tr>
              <td style="padding-left:1em;" rowspan="1" colspan="1"> 22</td>
              <td align="center" rowspan="1" colspan="1">1</td>
              <td align="center" rowspan="1" colspan="1">15</td>
              <td align="center" rowspan="1" colspan="1">M</td>
              <td align="center" rowspan="1" colspan="1">2</td>
              <td align="center" rowspan="1" colspan="1">ND</td>
              <td rowspan="1" colspan="1">TAE</td>
              <td align="center" rowspan="1" colspan="1">Died</td>
            </tr>
            <tr>
              <td style="padding-left:1em;" rowspan="1" colspan="1"> Our case</td>
              <td align="center" rowspan="1" colspan="1">1</td>
              <td align="center" rowspan="1" colspan="1">29</td>
              <td align="center" rowspan="1" colspan="1">F</td>
              <td align="center" rowspan="1" colspan="1">117.1</td>
              <td align="center" rowspan="1" colspan="1">15</td>
              <td rowspan="1" colspan="1">Surgical resection</td>
              <td align="center" rowspan="1" colspan="1">Alive</td>
            </tr>
          </tbody>
        </table>
        <table-wrap-foot>
          <fn>
            <p>F: female, M: male, ND: not described, TACE: transarterial chemoembolization, TAE: transarterial embolization</p>
          </fn>
        </table-wrap-foot>
      </table-wrap>
      <p>Thus, surveillance for HCC may be necessary in patients with CLD who undergo the Fontan procedure because cirrhosis is a high-risk factor for HCC. However, the screening interval for liver disease after the Fontan procedure has not yet been established. Surveillance is based on an ultrasound examination, and the recommended screening interval is 6 months according to the American Association for the Study of Liver Diseases (AASLD) practice guidelines on the management of HCC (<xref rid="B24" ref-type="bibr">24</xref>). In addition, the AFP level in the present case was high. In Japan (<xref rid="B25" ref-type="bibr">25</xref>), all patients with high-risk risk factors for HCC are advised to undergo periodic surveillance with US and laboratory work ups, including AFP and protein induced by vitamin K absence or antagonists-II (PIVKA-II), every 6 months. However, similar to the present case, PIVKA-II is not useful in most patients after the Fontan procedure because prophylactic antiplatelet with anticoagulation therapies, such as warfarin administration, are necessary to prevent thromboembolic events, which are one of the major causes of morbidity and mortality (<xref rid="B26" ref-type="bibr">26</xref>). Following the Fontan procedure, patients face a risk of HCC and require a lifelong follow-up with not only a pediatric cardiologist, but also a hepatologist experienced in the care of patients with liver cirrhosis.</p>
      <p>We herein described a patient with HCC who was able to safely undergo liver resection following the Fontan procedure under a preserved cardiac and hepatic function.</p>
    </sec>
    <sec>
      <title>The authors state that they have no Conflict of Interest (COI).</title>
    </sec>
  </body>
  <back>
    <ref-list>
      <ref id="B1">
        <label>1.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kendall</surname><given-names>TJ</given-names></name>, <name><surname>Stedman</surname><given-names>B</given-names></name>, <name><surname>Hacking</surname><given-names>N</given-names></name>, <etal>et al</etal></person-group>
<article-title>Hepatic fibrosis and cirrhosis in the Fontan circulation: a detailed morphological study</article-title>. <source>J Clin Pathol</source>
<volume>61</volume>: <fpage>504</fpage>-<lpage>508</lpage>, <year>2008</year>.<pub-id pub-id-type="pmid">17965217</pub-id></mixed-citation>
      </ref>
      <ref id="B2">
        <label>2.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wanless</surname><given-names>IR</given-names></name>, <name><surname>Liu</surname><given-names>JJ</given-names></name>, <name><surname>Butany</surname><given-names>J</given-names></name></person-group>
<article-title>Role of thrombosis in the pathogenesis of congestive hepatic fibrosis (cardiac cirrhosis)</article-title>. <source>Hepatology</source>
<volume>21</volume>: <fpage>1232</fpage>-<lpage>1237</lpage>, <year>1995</year>.<pub-id pub-id-type="pmid">7737628</pub-id></mixed-citation>
      </ref>
      <ref id="B3">
        <label>3.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaulitz</surname><given-names>R</given-names></name>, <name><surname>Luhmer</surname><given-names>I</given-names></name>, <name><surname>Bergmann</surname><given-names>F</given-names></name>, <name><surname>Rodeck</surname><given-names>B</given-names></name>, <name><surname>Hausdorf</surname><given-names>G</given-names></name></person-group>
<article-title>Sequelae after modified Fontan operation: postoperative haemodynamic data and organ function</article-title>. <source>Heart</source>
<volume>78</volume>: <fpage>154</fpage>-<lpage>159</lpage>, <year>1997</year>.<pub-id pub-id-type="pmid">9326989</pub-id></mixed-citation>
      </ref>
      <ref id="B4">
        <label>4.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Warnes</surname><given-names>CA</given-names></name>, <name><surname>Williams</surname><given-names>RG</given-names></name>, <name><surname>Bashore</surname><given-names>TM</given-names></name>, <etal>et al</etal></person-group>
<article-title>ACC/AHA 2008 guidelines for the management of adults with congenital heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Develop Guidelines on the Management of Adults With Congenital Heart Disease). Developed in Collaboration With the American Society of Echocardiography, Heart Rhythm Society, International Society for Adult Congenital Heart Disease, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons</article-title>. <source>J Am Coll Cardiol</source>
<volume>52</volume>: <fpage>e143</fpage>-<lpage>e263</lpage>, <year>2008</year>.<pub-id pub-id-type="pmid">19038677</pub-id></mixed-citation>
      </ref>
      <ref id="B5">
        <label>5.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Asrani</surname><given-names>SK</given-names></name>, <name><surname>Asrani</surname><given-names>NS</given-names></name>, <name><surname>Freese</surname><given-names>DK</given-names></name>, <etal>et al</etal></person-group>
<article-title>Congenital heart disease and the liver</article-title>. <source>Hepatology</source>
<volume>56</volume>: <fpage>1160</fpage>-<lpage>1169</lpage>, <year>2012</year>.<pub-id pub-id-type="pmid">22383293</pub-id></mixed-citation>
      </ref>
      <ref id="B6">
        <label>6.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schwartz</surname><given-names>MC</given-names></name>, <name><surname>Sullivan</surname><given-names>L</given-names></name>, <name><surname>Cohen</surname><given-names>MS</given-names></name>, <etal>et al</etal></person-group>
<article-title>Hepatic pathology may develop before the Fontan operation in children with functional single ventricle: an autopsy study</article-title>. <source>J Thorac Cardiovasc Surg</source>
<volume>143</volume>: <fpage>904</fpage>-<lpage>909</lpage>, <year>2012</year>.<pub-id pub-id-type="pmid">21955477</pub-id></mixed-citation>
      </ref>
      <ref id="B7">
        <label>7.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schwartz</surname><given-names>MC</given-names></name>, <name><surname>Sullivan</surname><given-names>LM</given-names></name>, <name><surname>Glatz</surname><given-names>AC</given-names></name>, <etal>et al</etal></person-group>
<article-title>Portal and sinusoidal fibrosis are common on liver biopsy after Fontan surgery</article-title>. <source>Pediatr Cardiol</source>
<volume>34</volume>: <fpage>135</fpage>-<lpage>142</lpage>, <year>2013</year>.<pub-id pub-id-type="pmid">22695765</pub-id></mixed-citation>
      </ref>
      <ref id="B8">
        <label>8.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kiesewetter</surname><given-names>CH</given-names></name>, <name><surname>Sheron</surname><given-names>N</given-names></name>, <name><surname>Vettukattill</surname><given-names>JJ</given-names></name>, <etal>et al</etal></person-group>
<article-title>Hepatic changes in the failing Fontan circulation</article-title>. <source>Heart</source>
<volume>93</volume>: <fpage>579</fpage>-<lpage>584</lpage>, <year>2007</year>.<pub-id pub-id-type="pmid">17005713</pub-id></mixed-citation>
      </ref>
      <ref id="B9">
        <label>9.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rockey</surname><given-names>DC</given-names></name></person-group>
<article-title>Current and future anti-fibrotic therapies for chronic liver disease</article-title>. <source>Clin Liver Dis</source>
<volume>12</volume>: <fpage>939</fpage>-<lpage>962, xi</lpage>, <year>2008</year>.<pub-id pub-id-type="pmid">18984475</pub-id></mixed-citation>
      </ref>
      <ref id="B10">
        <label>10.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goto</surname><given-names>T</given-names></name>, <name><surname>Mikami</surname><given-names>KI</given-names></name>, <name><surname>Miura</surname><given-names>K</given-names></name>, <etal>et al</etal></person-group>
<article-title>Mechanical stretch induces matrix metalloproteinase 1 production in human hepatic stellate cells</article-title>. <source>Pathophysiology</source>
<volume>11</volume>: <fpage>153</fpage>-<lpage>158</lpage>, <year>2004</year>.<pub-id pub-id-type="pmid">15561512</pub-id></mixed-citation>
      </ref>
      <ref id="B11">
        <label>11.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Simonetto</surname><given-names>DA</given-names></name>, <name><surname>Yang</surname><given-names>HY</given-names></name>, <name><surname>Yin</surname><given-names>M</given-names></name>, <etal>et al</etal></person-group>
<article-title>Chronic passive venous congestion drives hepatic fibrogenesis via sinusoidal thrombosis and mechanical forces</article-title>. <source>Hepatology</source>
<volume>61</volume>: <fpage>648</fpage>-<lpage>659</lpage>, <year>2015</year>.<pub-id pub-id-type="pmid">25142214</pub-id></mixed-citation>
      </ref>
      <ref id="B12">
        <label>12.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baek</surname><given-names>JS</given-names></name>, <name><surname>Bae</surname><given-names>EJ</given-names></name>, <name><surname>Ko</surname><given-names>JS</given-names></name>, <etal>et al</etal></person-group>
<article-title>Late hepatic complications after Fontan operation; non-invasive markers of hepatic fibrosis and risk factors</article-title>. <source>Heart</source>
<volume>96</volume>: <fpage>1750</fpage>-<lpage>1755</lpage>, <year>2010</year>.<pub-id pub-id-type="pmid">20956491</pub-id></mixed-citation>
      </ref>
      <ref id="B13">
        <label>13.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pike</surname><given-names>NA</given-names></name>, <name><surname>Evangelista</surname><given-names>LS</given-names></name>, <name><surname>Doering</surname><given-names>LV</given-names></name>, <name><surname>Koniak-Griffin</surname><given-names>D</given-names></name>, <name><surname>Lewis</surname><given-names>AB</given-names></name>, <name><surname>Child</surname><given-names>JS</given-names></name></person-group>
<article-title>Clinical profile of the adolescent/adult Fontan survivor</article-title>. <source>Congenit Heart Dis</source>
<volume>6</volume>: <fpage>9</fpage>-<lpage>17</lpage>, <year>2011</year>.<pub-id pub-id-type="pmid">21269408</pub-id></mixed-citation>
      </ref>
      <ref id="B14">
        <label>14.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Camposilvan</surname><given-names>S</given-names></name>, <name><surname>Milanesi</surname><given-names>O</given-names></name>, <name><surname>Stellin</surname><given-names>G</given-names></name>, <name><surname>Pettenazzo</surname><given-names>A</given-names></name>, <name><surname>Zancan</surname><given-names>L</given-names></name>, <name><surname>D'Antiga</surname><given-names>L</given-names></name></person-group>
<article-title>Liver and cardiac function in the long term after Fontan operation</article-title>. <source>Ann Thorac Surg</source>
<volume>86</volume>: <fpage>177</fpage>-<lpage>182</lpage>, <year>2008</year>.<pub-id pub-id-type="pmid">18573420</pub-id></mixed-citation>
      </ref>
      <ref id="B15">
        <label>15.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ghaferi</surname><given-names>AA</given-names></name>, <name><surname>Hutchins</surname><given-names>GM</given-names></name></person-group>
<article-title>Progression of liver pathology in patients undergoing the Fontan procedure: Chronic passive congestion, cardiac cirrhosis, hepatic adenoma, and hepatocellular carcinoma</article-title>. <source>J Thorac Cardiovasc Surg</source>
<volume>129</volume>: <fpage>1348</fpage>-<lpage>1352</lpage>, <year>2005</year>.<pub-id pub-id-type="pmid">15942576</pub-id></mixed-citation>
      </ref>
      <ref id="B16">
        <label>16.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saliba</surname><given-names>T</given-names></name>, <name><surname>Dorkhom</surname><given-names>S</given-names></name>, <name><surname>O'Reilly</surname><given-names>EM</given-names></name>, <name><surname>Ludwig</surname><given-names>E</given-names></name>, <name><surname>Gansukh</surname><given-names>B</given-names></name>, <name><surname>Abou-Alfa</surname><given-names>GK</given-names></name></person-group>
<article-title>Hepatocellular carcinoma in two patients with cardiac cirrhosis</article-title>. <source>Eur J Gastroenterol Hepatol</source>
<volume>22</volume>: <fpage>889</fpage>-<lpage>891</lpage>, <year>2010</year>.<pub-id pub-id-type="pmid">19550346</pub-id></mixed-citation>
      </ref>
      <ref id="B17">
        <label>17.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Asrani</surname><given-names>SK</given-names></name>, <name><surname>Warnes</surname><given-names>CA</given-names></name>, <name><surname>Kamath</surname><given-names>PS</given-names></name></person-group>
<article-title>Hepatocellular carcinoma after the Fontan procedure</article-title>. <source>N Engl J Med</source>
<volume>368</volume>: <fpage>1756</fpage>-<lpage>1757</lpage>, <year>2013</year>.<pub-id pub-id-type="pmid">23635071</pub-id></mixed-citation>
      </ref>
      <ref id="B18">
        <label>18.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Elder</surname><given-names>RW</given-names></name>, <name><surname>Parekh</surname><given-names>S</given-names></name>, <name><surname>Book</surname><given-names>WM</given-names></name></person-group>
<article-title>More on hepatocellular carcinoma after the Fontan procedure</article-title>. <source>N Engl J Med</source>
<volume>369</volume>: <fpage>490</fpage>, <year>2013</year>.<pub-id pub-id-type="pmid">23902510</pub-id></mixed-citation>
      </ref>
      <ref id="B19">
        <label>19.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rajoriya</surname><given-names>N</given-names></name>, <name><surname>Clift</surname><given-names>P</given-names></name>, <name><surname>Thorne</surname><given-names>S</given-names></name>, <name><surname>Hirschfield</surname><given-names>GM</given-names></name>, <name><surname>Ferguson</surname><given-names>JW</given-names></name></person-group>
<article-title>A liver mass post-Fontan operation</article-title>. <source>QJM</source>
<volume>107</volume>: <fpage>571</fpage>-<lpage>572</lpage>, <year>2014</year>.<pub-id pub-id-type="pmid">24623858</pub-id></mixed-citation>
      </ref>
      <ref id="B20">
        <label>20.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weyker</surname><given-names>PD</given-names></name>, <name><surname>Allen-John Webb</surname><given-names>C</given-names></name>, <name><surname>Emond</surname><given-names>JC</given-names></name>, <name><surname>Brentjens</surname><given-names>TE</given-names></name>, <name><surname>Johnston</surname><given-names>TA</given-names></name></person-group>
<article-title>Anesthetic implications of extended right hepatectomy in a patient with fontan physiology</article-title>. <source>A A Case Rep</source>
<volume>2</volume>: <fpage>99</fpage>-<lpage>101</lpage>, <year>2014</year>.<pub-id pub-id-type="pmid">25611770</pub-id></mixed-citation>
      </ref>
      <ref id="B21">
        <label>21.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kwon</surname><given-names>S</given-names></name>, <name><surname>Scovel</surname><given-names>L</given-names></name>, <name><surname>Yeh</surname><given-names>M</given-names></name>, <etal>et al</etal></person-group>
<article-title>Surgical management of hepatocellular carcinoma after Fontan procedure</article-title>. <source>J Gastrointest Oncol</source>
<volume>6</volume>: <fpage>E55</fpage>-<lpage>E60</lpage>, <year>2015</year>.<pub-id pub-id-type="pmid">26029468</pub-id></mixed-citation>
      </ref>
      <ref id="B22">
        <label>22.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamada</surname><given-names>K</given-names></name>, <name><surname>Shinmoto</surname><given-names>H</given-names></name>, <name><surname>Kawamura</surname><given-names>Y</given-names></name>, <etal>et al</etal></person-group>
<article-title>Transarterial embolization for pediatric hepatocellular carcinoma with cardiac cirrhosis</article-title>. <source>Pediatr Int</source>
<volume>57</volume>: <fpage>766</fpage>-<lpage>770</lpage>, <year>2015</year>.<pub-id pub-id-type="pmid">26013052</pub-id></mixed-citation>
      </ref>
      <ref id="B23">
        <label>23.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Llovet</surname><given-names>JM</given-names></name>, <name><surname>Burroughs</surname><given-names>A</given-names></name>, <name><surname>Bruix</surname><given-names>J</given-names></name></person-group>
<article-title>Hepatocellular carcinoma</article-title>. <source>Lancet</source>
<volume>362</volume>: <fpage>1907</fpage>-<lpage>1917</lpage>, <year>2003</year>.<pub-id pub-id-type="pmid">14667750</pub-id></mixed-citation>
      </ref>
      <ref id="B24">
        <label>24.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bruix</surname><given-names>J</given-names></name>, <name><surname>Sherman</surname><given-names>M</given-names></name>; <collab>American Association for the Study of Liver D</collab>. </person-group><article-title>Management of hepatocellular carcinoma: an update</article-title>. <source>Hepatology</source>
<volume>53</volume>: <fpage>1020</fpage>-<lpage>1022</lpage>, <year>2011</year>.<pub-id pub-id-type="pmid">21374666</pub-id></mixed-citation>
      </ref>
      <ref id="B25">
        <label>25.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kudo</surname><given-names>M</given-names></name>, <name><surname>Izumi</surname><given-names>N</given-names></name>, <name><surname>Kokudo</surname><given-names>N</given-names></name>, <etal>et al</etal></person-group>
<article-title>Management of hepatocellular carcinoma in Japan: Consensus-Based Clinical Practice Guidelines proposed by the Japan Society of Hepatology (JSH) 2010 updated version</article-title>. <source>Dig Dis</source>
<volume>29</volume>: <fpage>339</fpage>-<lpage>364</lpage>, <year>2011</year>.<pub-id pub-id-type="pmid">21829027</pub-id></mixed-citation>
      </ref>
      <ref id="B26">
        <label>26.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Monagle</surname><given-names>P</given-names></name>, <name><surname>Karl</surname><given-names>TR</given-names></name></person-group>
<article-title>Thromboembolic problems after the Fontan operation</article-title>. <source>Semin Thorac Cardiovasc Surg Pediatr Card Surg Annu</source>
<volume>5</volume>: <fpage>36</fpage>-<lpage>47</lpage>, <year>2002</year>.<pub-id pub-id-type="pmid">11994863</pub-id></mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
